Potent immunogenicity in BRCA1‐mutated patients with high‐grade serous ovarian carcinoma

High‐grade serous ovarian carcinomas (HGSOCs) were among the tumours with an unsatisfactory outcome of immune checkpoint inhibitors (ICIs). It is imperative to develop feasible biomarker for identifying responsive candidates and guiding precise immunotherapy for HGSOC patients. Here, we analysed gen...

Descripción completa

Detalles Bibliográficos
Autores principales: Dai, Ying, Sun, Chengdu, Feng, Yi, Jia, Qingzhu, Zhu, Bo
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2018
Materias:
Original Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050488/
https://www.ncbi.nlm.nih.gov/pubmed/29855141
http://dx.doi.org/10.1111/jcmm.13678

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6050488/
https://www.ncbi.nlm.nih.gov/pubmed/29855141
http://dx.doi.org/10.1111/jcmm.13678

Ejemplares similares